カリフォルニア州におけるびまん性強皮症の臨床試験
カリフォルニア州内の拠点で、びまん性強皮症に関する9件の研究が参加者を募集しています。
カリフォルニア州内の都市
公式研究テキスト（英語）
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
- UCLA, Los Angeles
- Hoag Hospital, Newport Beach
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/09/28更新 · NCT06470048EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- EncompaSSc site in La Jolla, CA, La Jolla
- EncompaSSc site in Loma Linda, CA, Loma Linda
- University of California Los Angeles Scleroderma Center, Los Angeles
- 他2件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT07287670A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
被験者募集中第1相
18歳〜74歳 · 全性別 · 2026/09/10更新 · NCT07085104A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- GSK Investigational Site, Los Angeles
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06716606A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- 他1件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT05878717A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- UC San Diego Health, La Jolla
- Stanford University Medical Center, Redwood City
被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/08/28更新 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- Keck School of Medicine at USC Medical Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Stanford University Medical Center, Palo Alto
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/18更新 · NCT06195072A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Orange
被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/08/07更新 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Chula Vista, Chula Vista
- Artiva Investigational Site Covina, Covina
- Artiva Investigational Site Los Alamitos, Los Alamitos
- 他3件
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/31更新 · NCT06991114ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。